Latest Breaking News On - Servier pharmaceuticals - Page 1 : comparemela.com

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients

Adagrasib, Cetuximab May Benefit KRASG12c Colorectal Cancer Patients

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

16 APRIL 2024 AT 15:00 (CEST) - Form 6-K -March 29, 2024 at 08:34 am EDT

16 APRIL 2024 AT 15:00 at Evaxion Biotech A/S, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. AGENDA 1.Election of the chairman of the.

Tibsovo Market Expected to Surge with a CAGR of Approximately 5.1% by 2030

Market OverviewTibsovo (ivosidenib) is a targeted cancer therapy developed by Agios Pharmaceuticals, Inc. It is an oral, small molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is mutated in various types of cancers, including acute myeloid leukemia (AML), cholangiocarcinoma, and glioma. Tibs.